This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Barrios, V. Articles by Fernandez, R. Search for Related Content PubMed PubMed Citation Articles by Barrios, V. Articles by Fernandez, R. Social Bookmarking                         What's this?

Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice The VIPE study

Department of Cardiology, Hospital Ramon y Cajal, Madrid, vbarriosa{at}meditex.es, vbarrios.hrc{at}salud.madrid.org

Carlos Escobar

Department of Cardiology, Hospital Ramon y Cajal, Madrid

Alberto Calderon

Primary Health Care Centre Rosa de Luxemburgo, Madrid

Juan Pablo Tomás

Department of Cardiology, Hospital Ramon y Cajal, Madrid

Soledad Ruiz

Department of Cardiology, Hospital Ramon y Cajal, Madrid

Jose Luis Moya

Department of Cardiology, Hospital Ramon y Cajal, Madrid

Alicia Megias

Department of Cardiology, Hospital Ramon y Cajal, Madrid

Onofre Vegazo

AstraZeneca Medical Department, Madrid, Spain

Raul Fernandez

AstraZeneca Medical Department, Madrid, Spain

The VIPE study was a prospective, non-comparative, open-label clinical evaluation of 97 hypertensive patients (69.1% female; 68.9±9.5 years; mean blood pressure (BP) 160±12/90±9 mmHg) with echocardiographic evidence of left ventricular hypertrophy (LVH). Patients were treated for six months with a candesartan-based regimen (8 mg/16 mg + HCTZ 12.5 mg + additional drugs to lower BP < 140/90 mmHg). After six months, systolic/diastolic BP was decreased by 19.3±8/9.4±5 mmHg (p<0.001 for both), and left ventricular mass index (LVMI) decreased 17.01 g/m2 (95%CI: -13.2 to -20.99; p<0.001). During treatment with the candesartan-based regimen all echocardiographic parameters related to LVMI were significantly reduced and 28% achieved a target LVMI [< 134 g/m2 (men) and < 110 g/m² (women) ]. No significant changes were observed in ejection fraction, shortening fraction or LV diastolic function. Univariate analysis showed that both age (p=0.03) and diabetes (p=0.029) were predictive of LVH regression.

Thus, a candesartan-based regimen for six months significantly reduced echocardiographic LVH in hypertensive patients in general practice. The drug was very well tolerated and no serious adverse events were reported.

Key Words: candesartan hypertension left ventricular hypertrophy • regression

Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 4, 236-242 (2006)
DOI: 10.3317/jraas.2006.044


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				V. Barrios, C. Escobar, A. Calderon, R. Echarri, S. Barrios, and J. Navarro-Cid Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study Journal of Renin-Angiotensin-Aldosterone System, September 1, 2009; 10(3): 168 - 173. [Abstract] [PDF]

				C. Escobar and V. Barrios Gender Differences in Left Ventricular Hypertrophy Regression Hypertension, June 1, 2008; 51(6): e58 - e58. [Full Text] [PDF]